Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 7/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | PARG | Q86W56 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709045 | 0.86 | FEN1 (0.66) | FEN1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL8215674 | 0.81 | ADORA3 (0.61) | ADORA3ADORA2AADORA2BADORA1PARG | |
| SCHEMBL9923029 | 0.79 | ADORA3 (0.59) | FEN1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL31709875 | 0.79 | ADORA3 (0.64) | ADORA3ADORA2AADORA2BADORA1PARG | |
| SCHEMBL18670476 | 0.79 | FEN1 (1.00) | FEN1MPOKEAP1NFE2L2XDH | |
| SCHEMBL5355203 | 0.79 | CA12 (0.66) | FEN1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL9919007 | 0.79 | CA9 (0.66) | ADORA3ADORA2AADORA2BADORA1MPO | |
| SCHEMBL9919008 | 0.79 | ADORA3 (0.64) | ADORA3ADORA2AADORA2BADORA1PARG | |
| SCHEMBL5712368 | 0.79 | ADORA3 (0.59) | FEN1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL22745955 | 0.79 | FEN1 (0.60) | FEN1MPOKEAP1NFE2L2XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2022-06-02 | — | — | US | disclosed |
| EP-2314593-B1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| EP-0226282-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | A/S FERROSAN (DK) | 1989-07-05 | — | — | EP | disclosed |
| US-4780539-A | ANTICONVULSANTS, ANXIOLYTIC AGENTS | A/S FERROSAN (DK) | 1988-10-25 | — | — | US | disclosed |
| US-4771051-A | CENTRAL NERVOUS SYSTEM DISORDERS | A/S FERROSAN (DK) | 1988-09-13 | — | — | US | disclosed |
| EP-0274009-A1 | Oxadiazolylacetonitriles, their preparation and use | NOVO NORDISK A/S (DK) | 1988-07-13 | — | — | EP | disclosed |
| EP-0226282-A2 | Heterocyclic compounds and their preparation and use | A/S FERROSAN (DK) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | FEN1 3974/4885ADORA3 32/4885ADORA2A 18/4885 |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | PPOX, CYCS, SCO2 | FEN1 2304/4885ADORA3 431/4885ADORA2A 950/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | FEN1 4319/4885ADORA3 83/4885ADORA2A 41/4885 |
| US-20140221405-A1 | PLATELET ADP RECEPTOR INHIBITORS | PTAFR, ADGRF1, P2RY6 | FEN1 3688/4885ADORA3 20/4885ADORA2A 12/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | FEN1 365/4885ADORA3 2542/4885ADORA2A 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.